Cover Image
Market Research Report

Global Markets Non-antibiotic Bacterial Therapeutics

Published by Greystone Research Associates Product code 803192
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Global Markets Non-antibiotic Bacterial Therapeutics
Published: March 10, 2019 Content info:
Description

Novel Approaches Signaling a Shift in Bacterial Therapeutics

As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides currently undergoing clinical trials. The specificity of antibodies, and the inability of bacteria to develop resistance against them, make antibodies attractive, albeit expensive, alternative therapeutic agents. Bacteriophages have been used for therapy in some parts of the world. Antimicrobial peptides have long been considered as potential replacements for antibiotics but with limited success. Synthetic peptides and synthetic Antibiotic membrane-active agents might herald a shift.

Non-antibiotic Bacterial Therapeutics - What You Will Learn:

  • What are the classes of non-antibiotics drugs that can treat bacterial infections alone or in conjunction with existing antibiotics?
  • What non-antibiotic bacterial therapies are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving demand for non-antibiotic bacterial treatments?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2024?
  • What are the essential factors, technologies and market development issues for non-antibiotic bacterial therapeutics products?
  • What are the significant economic, technology, and regulatory factors affecting the market for non-antibiotic Bacterial Therapies
Table of Contents
Product Code: NBT448K

Table of Contents

  • Executive Summary
  • Market Dynamics
  • The Unmet Need
  • Defining the Scope
  • The Evolving Landscape
  • Technology
  • Antibodies
  • Antibiotic-deactivating Enzymes
  • Bacteriophages
  • Antimicrobial peptides
  • Antimicrobial Nanoparticles
  • Antisense therapy/gene silencing
  • Active extrusion of bacterial compounds/membrane pumps
  • Siderophores
  • Non-antibiotic Microbial Therapeutics - Therapies
  • Antibodies
  • Lysins
  • Phages
  • Antimicrobial Peptides
  • Defensins
  • Host Directed Therapies
  • Non-antibiotic Bacterial Therapeutics - Primary Targets
  • Clamydia
  • Clostridium Difficile
  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Mycobacteria Tubercolosis
  • Private Research
  • Univ of Hong Kong
  • Case Western
  • Boston's Children's Hospital
  • Global Market Regulations and Standards
  • North America
  • US FDA
  • US Centers for Disease Control
  • Europe
  • European Centre for Disease Prevention and Control
  • Asia
  • Chinese Center for Disease Control and Prevention
  • National Centre for Disease Control (India)
  • Company Profiles
Back to Top